ไวบกรอน: ยาตวใหมสำหรบรกษาภาวะกระเพาะปสสาวะบบตวไวเกน
Abstract
Overactive bladder is a common condition among older adults and has an impact on quality of life. Current standard treatment includes anticholinergic agents; however, these medications are associated with various adverse effects that may limit treatment adherence. Consequently, newer therapeutic agents with improved efficacy and safety profiles have been developed, including vibegron, a β3-adrenergic receptor agonist. Based on evidence from comparative literature reviews, vibegron was found to significantly reduce urinary frequency, urgency episodes, and urgency urinary incontinence with statistically significant improvements. Regarding safety, adverse event rates were low and comparable to the placebo. Therefore, vibegron is effective and safe for the management of overactive bladder.
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.